We provide the latest news
from the world of economics and finance
(RTTNews) - Clearmind Medicine Inc. (CMND) Tuesday said it has submitted an additional patent application with the United States Patent and Trademark Office, as part of its ongoing collaborations with SciSparc Ltd. (SPRC).
The patent application refers to the novel proprietary composition of Clearmind's MEAI compound, 5-methoxy-2-aminoindane with Palmitoylethanolamide, the active ingredient of SciSparc's proprietary CannAmide, for treating metabolic syndrome and obesity.
As part of the collaboration with SciSparc, twelve other patent applications have been filed by Clearmind for various proprietary compositionss, including the composition of SciSparc's Palmitoylethanolamide with Clearmind's MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.